Chengdu Olymvax Stock Hits Day Low Amid Price Pressure, Drops to CNY 28.66

Chengdu Olymvax Biopharmaceuticals, Inc. experienced a significant decline today, with the stock dropping by 8.24% as it reached an intraday low of CNY 28.66. This performance stands in contrast to the China Shanghai Composite, which saw a modest decrease of 0.26% on the same day. Over the past week, Chengdu Olymvax has faced a decline of 5.8%, while its performance over the past month shows a gain of 5.9%. Notably, the stock has demonstrated impressive growth over the past year, with a remarkable increase of 98.41%, significantly outperforming the China Shanghai Composite's 19.45% gain. Financial metrics indicate a robust position for the company, with a net sales growth of 25.38% reported in September. The company has also shown strong returns on capital employed, with a highest recorded ROCE of 6.86%. Additionally, the interest coverage ratio stands at an impressive 1,289.5, reflecting solid financial health. Chengdu Olymvax's market capitalization is currently CNY 7,820 million, and it maintains a low debt-to-equity ratio of 0.18, further underscoring its stability in the pharmaceuticals and biotechnology sector.